ECG measures of Fabry cohort on enzyme replacement
| Post-treatment | Baseline | Year 1 | Year 2 | Year 5 | Year 7 | Year 10 |
|---|---|---|---|---|---|---|
| PR (ms) | ||||||
| Non-CKD5 | 154.0±25.7 | 155.1±26.1 | 153.9±24.7 | 153.5±25.3 | 151.6±29.0 | 148.2±34.3 |
| CKD5 | 154.6±23.5 | 153.8±22.8 | 145.7±18 | 142.3±16.6 | 143.7±18.0 | 152±7.6 |
| QRS (ms) | ||||||
| Non-CKD5 | 99.6±8.8 | 99.2±19.6 | 102.9±11.3 | 103.5±13.1 | 103.4±10.9 | 106.3±20.5 |
| CKD5 | 110.9±44.0 | 112±32.9 | 127.8±44.4 | 111.4±28.9 | 115.2±26.5 | 123±36.4 |
| QT (ms) | ||||||
| Non-CKD5 | 377.9±30.7 | 375.7±33.7 | 377.7±14.2 | 376.7±20.6 | 384.4±17.2 | 395.1±30.5 |
| CKD5 | 382.9±51.2 | 401.4±37.6 | 401±27.0 | 409.3±39.3 | 420±27.6 | 432±30.3 |
| QTc (ms) | ||||||
| Non-CKD5 | 365.4±24.2 | 358.9±25.6 | 356.4±19.3 | 352.9±18.1 | 356.4±30.3 | 366.3±30.3 |
| CKD5 | 384.6±26.6 | 387.7±19.7 | 388.5±18.9 | 404.7±16.8 | 411.5±21.3 | 418.4±26.9 |
Non-CKD5 cohort size: baseline (N=20), year 1 (N=20), year 2 (N=20), year 5 (N=16), year 7 (N=16) and year 10 (N=11).
CKD5 cohort size: baseline (N=9), year 1 (N=10), year 2 (N=9), year 5 (N=6), year 7 (N=6) and year 10 (N=5).
Two-way ANOVA comparing CKD5 with non-CKD5 for parameters QRS, QT and QTc over the duration of treatment were statistically different (p=0.004, p<0.0001 and p<0.0001, respectively) while PR was unchanged (p=0.41).
ANOVA, analysis of variance; CKD5, chronic kidney disease stage 5.